Group items tagged

This project will investigate in vitro - in vivo correlations of topical dermatological products. The project has several phases as noted below: 1) Selection or manufacture of test formulations. The formulations should contain the same active ingredient and have different inactive ingredients. They may be currently marketed formulation. 2) Identification or generation of the in vivo data set. The in vivo data set may be obtained from the literature or generated as a part of this grant. In vivo performance could be assessed by either human PK data, human microdialysis data or any other proposed source. 3) In vitro in vivo correlation: The test formulations should be evaluated under a range of in vitro release test conditions. In vitro release tests could include using excised human skin or artificial membranes. 4) Optimization of the in vitro release testing protocol. The in vitro release test protocol with the best prediction of in vivo results should be identified. 5) A protocol for the external validation of the optimal method should be developed

JDRF is launching an initiative to accelerate the development of "open-protocol" automated insulin delivery (artificial pancreas) systems. JDRF is soliciting proposals from insulin pump manufacturers and continuous glucose monitor (CGM) manufacturers that will enable seamless, secure connectivity with other devices (e.g., by using Bluetooth technology). JDRF remains committed to supporting the traditional, proprietary commercial development of artificial pancreas systems; in parallel, JDRF will launch efforts in the United States and globally to partner with regulators and legal experts to establish predictable approval pathways for systems that allow for secure, open-protocol-based control through commercially developed devices and software

Dr. Daniel Stephens of Stephens Consulting has been studying and monitoring Neotropical birds in the Douglas Creek riparian corridor for the past 20 years to provide long term population and demographic information on target land bird species. Having all of the necessary and appropriate certifications and permits required to legally capture migratory birds, Dr. Stephens has been banding birds in this area as part of the larger global effort known as Monitoring Avian Production and Survivorship (MAPS). Long term studies with continuous data collection in one site are vital for bird banding studies like the continent-wide MAPS study. Collected data is submitted to the Institute for Bird Populations following the MAPS Protocol with results being published in the journal "BIRD Populations: A journal of global avian demography and biogeography." The objective of this program is to continue to study and monitor Neotropical birds in the Douglas Creek riparian corridor during the annual summer period of use. Data collected on species captured and unique identification will be entered into a global database monitored by the Institute for Bird Populations following the MAPS Protocol.

The purpose of this FOA is to identify and support a Clinical Coordination Center (CCC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The Clinical Coordinating Center is expected to serve as the hub for the Multisite Clinical Centers (below) to support study design, efficiency, progress, and quality, and to coordinate and monitor study implementation across the clinical sites. The Clinical Coordinating Center will lead the consortium in developing and implementing standardized protocols, safety standards, staff training protocols, electronic health record (EHR) data standards, patient phenotyping and testing, and regulatory processes.

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.

This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.

This Limited Competition Funding Opportunity Announcement (FOA) invites an application from the currently funded NIH Common Fund-supported Extracellular RNA Communication Consortium (ERCC) Data Management and Resource Repository (DMRR) to support Stage 2 efforts of this program.  The overall programmatic goal of the DMRR is to integrate the efforts of all funded components of the ERCC and serve as a community-wide resource for extracellular RNA (exRNA) standards, protocols, and data. 

Shwachman-Diamond Syndrome Foundation (SDSF) is a nonprofit support organization actively helping the victims of this disease. SDSF is accepting grant requests for research relevant to this disease. Any high quality, innovative research proposal deemed relevant to SDS will be considered. The following are areas of particular interest: Investigate or evaluate potential novel therapies or potential novel therapeutic strategies- preferred applications Evaluate predictors of bone marrow abnormalities to determine their correlation with the disease Determine the causes of and investiagte treatments for bone marrow failure and leukemia Evaluate protocols and regimens for bone marrow transplants Evaluate causes and investigate treatments for graft vs host disease and other infections of post bone marrow transplants Investigations related to adult patient presentation, management, and care including transition from pediatric-centered to adult care

In 2017, the Pancreatic Cancer Action Network will invest $12.8 million in innovative research related to pancreatic cancer, a 33 percent increase over 2016. This investment includes both the network's competitive, peer-reviewed Research Grants Program and its internal research initiatives. To that end, the network has issued an RFA for its Early Detection Targeted Grant program, through which grants of up to $1 million over four years will be awarded to support ancillary research studies that identify promising blood biomarkers or imaging approaches with the potential to facilitate the use of specimens and/or participants in a cohort of new-onset diabetics and to validate components of a protocol for the early detection of pancreatic ductal adenocarcinoma.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-​effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC&'s current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. APPLY FOR A GRANT Sign up for our newsletter

The purpose of this project is to yield protocols for the presence/absence eDNA detection of the S. hineana and C. diogenes under a range of environmental conditions. It will provide the information critical to evaluating the probability of false negatives or positives, and the understanding the general role that eDNA detection will play in conserving this endangered insect.

The overarching goals of this Funding Opportunity Announcement (FOA) and the companion announcement (RFA-RM-13-011) are to foster the development of technologies and information management to facilitate the unveiling of the functions of the poorly characterized and/or un-annotated members in four protein classes of the Druggable Genome. This FOA calls for adaptation of an ensemble of scalable technology platforms to characterize functions of proteins as a large group at molecular and cellular levels in medium- to high-throughput fashion, rather than repeating the one at a time approach that might otherwise be undertaken. The objective is to establish transformative scalable technology platforms and streamlined experimental workflows incorporated with multiple robust assay and physiological perturbation protocols for large-scale functional studies of poorly characterized and/or un-annotated proteins encoded by the Druggable Genome.

Through its Mentoring Active Learning and Teaching initiative, ASCB will award grants of up to $2,000 for individual undergraduate biology educators to visit, observe, and work with mentors skilled in active-learning strategies and evidence-based teaching that align with the society's principles of vision and change. This immersion/mentoring experience is intended to provide clarity and practical interactive opportunities for MALT Fellows so they can analyze particular elements of teaching protocols; ask timely, pointed questions about how to activate them in their own classrooms and disciplines; and immediately put their new skills into practice. The program also provides a $500 stipend for the mentor.

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications from public nonprofit institutions/organizations (includes institutions of higher education and hospitals) to perform research and analysis of data to inform drug policy. This project seeks to further refine a methodology for obtaining drug early warning indicators from expanded testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations - including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. 

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

Studies funded by our Basic Research RFP will fall into one the following key areas, which are listed in random order: 1. Studies focused on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function. Results should lead to a better understanding of the requirements for SMN protein biologically, informing therapy development. Such studies may also identify genetic modifiers, upstream regulators of SMN expression / splicing / function, and downstream effectors of SMN functional activity, resulting in novel drug targets.      2.  Studies resulting in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models of the SMA. This includes focus on the tissue requirements for SMN protein, clarifying the cellular autonomy of the disease in motor neurons and other cells, peripheral versus central manifestations of the disease, and other areas.  3. Early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models of the disease. 4. Work focused on generating research and clinical trial tools, such as new animal models for SMA, phenotypic cellular assays for SMA, biomarkers or outcome measures for SMA clinical trials, newborn screening protocols, and others.

The purpose of this Funding Opportunity Announcement (FOA) is to continue addressing two critical scientific questions on the clinical course of perinatally acquired HIV infection in adolescents and the oral and systemic health consequences of in utero and infant exposure to antiretroviral chemotherapy in representative cohorts of children in the United States. The CC is responsible for maintaining the Scientific Leadership Group (SLG) through performance-based subcontracts. The SLG should continue to have scientific specialty working groups to reflect the different disciplines required to successfully implement the protocols and substudies.

The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements.